Table 5

Cumulative survival parameter estimates in patients with APACHE II >= 25

Drotrecogin alfa


Cumulative survival

PROWESS

ADDRESS

Point estimate Pooled results (± SD)


28-day

69.1% [2]

70.5%[14]

69.45% (± 3.55)

3-month

58.9% [8]

NA

58.9% (± 2.42)

6-month

55.2% [8]

NA

55.2% (± 2.44)

12-month

52.1% [8]

NA

52.1% (± 2.46)

30-month

45.6% [8]

NA

45.6% (± 2.45)


Placebo


Cumulative survival

PROWESS

ADDRESS

Pooled results (± SD)


28-day

56.3% [2]

75.3% [14]

62.93% (± 3.40)

3-month

48.4% [8]

NA

48.4% (± 2.49)

6-month

45.3% [8]

NA

45.3% (± 2.48)

12-month

41.3% [8]

NA

41.3% (± 2.45)

30-month

33.8% [8]

NA

33.8% (± 2.36)


CI = confidence interval/NA = not available/SA = sensitivity analysis/SD = standard deviation

* Calculated according to the information provided in the studies.

Costa and Brophy BMC Anesthesiology 2007 7:5   doi:10.1186/1471-2253-7-5

Open Data